Immatics combines the discovery of cancer targets with T cell receptor development to create Adoptive Cell Therapies and TCR Bispecifics.
Immatics Biotechnologies GmbHPaul-Ehrlich-Str. 15 – 19
72076 Tübingen
Germany • Baden-Württemberg • Tübingen
T cell receptors development